Overview

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

Status:
Completed

Trial end date:
2019-12-12

Target enrollment:

Participant gender:

Summary

The purpose of this open-label extension study is to evaluate long-term efficacy and safety of roxadustat in maintaining hemoglobin (Hb) in participants with dialysis and non-dialysis chronic kidney disease (CKD) who have completed the Treatment Period of a roxadustat FibroGen-sponsored anemia study.

Phase:

Phase 2

Details

Lead Sponsor:

FibroGen

Collaborators:

Astellas Pharma Inc
AstraZeneca